anagrelide

(redirected from Agrelin)

anagrelide

 [an-ag´rĕ-līd]
an agent used in the form of the hydrochloride salt to reduce elevated platelet counts and the risk of thrombosis in treatment of hemorrhagic thrombocythemia; administered orally.

anagrelide

/an·ag·re·lide/ (an-ag´rĕ-līd) an agent used to reduce elevated platelet counts and the risk of thrombosis in the treatment of hemorrhagic thrombocythemia; used as the hydrochloride salt.

anagrelide

an antiplatelet agent.
indication This drug is prescribed for essential thrombocythemia.
contraindications Known hypersensitivity and hypotension prohibit its use.
adverse effects Life-threatening effects include congestive heart failure, myocardial infarction, myocardiopathy, cardiomegaly, complete heart block, atrial fibrillation, anemia, thrombocytopenia, ecchymosis, and lymphadenoma. Other serious effects include tachycardia, palpitations, arrhythmia, and seizures. Common side effects include orthostatic hypotension and rash.

anagrelide

A cytoreductive agent used to manage essential thrombocythaemia and thrombocythaemia due to myeloproliferative disorders (e.g., CML, polycythemia vera) to reduce platelets, risk of thrombosis and other symptoms. It is generally regarded as a second-line therapy compared to hydroxyurea.

Anagrelide

An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Mentioned in: Polycythemia Vera
References in periodicals archive ?
Agrelin, an anagrelide, is indicated for preventing strokes in patients with thrombocytosis (which is an overabundance of platelets).
Roberts expects to file a new drug application for Agrelin sometime early this year.